Macrofauna asociada al alga stypocaulon scoparium en el Estrecho de Gibraltar y comparación con el resto de la Península Ibérica

Se estudió la macrofauna asociada al alga Stypocaulon scoparium en el estrecho de Gibraltar y el resto de la península Ibérica. Se seleccionaron un total de 14 estaciones, 3 de ellas localizadas en el Estrecho y las 11 restantes distribuidas en las costas cantábricas, atlánticas y mediterráneas de la península Ibérica. En cada estación se midieron parámetros fisicoquímicos (temperatura, oxígeno disuelto, conductividad, pH y turbidez), se estimó la cobertura del alga y se recolectaron muestras de la misma en el submareal somero (1- 3 m de profundidad) mediante buceo en apnea. Se separaron e identificaron un total de 48.430 individuos pertenecientes a 16 grupos distintos de artrópodos, moluscos, anélidos y equinodermos. Atendiendo a los parámetros fisicoquímicos, los análisis de clasificación mostraron una mayor similaridad del área del Estrecho con las estaciones atlánticas. La costa mediterránea se caracterizó por una mayor temperatura y conductividad, mientras que la atlántica mostró valores más altos de oxígeno disuelto y turbidez, consecuencia un mayor oleaje. La cobertura del alga S. scoparium fue significativamente mayor en el Estrecho de Gibraltar que en las estaciones restantes y se registró una mayor diversidad de invertebrados asociados a este alga en el Estrecho que en otras zonas de la Península. Los crustáceos anfípodos fueron los más abundantes, seguidos de poliquetos y moluscos gasterópodos. El Análisis Canónico de Correspondencias (CCA) mostró que anfípodos, isópodos, quironómidos y crinoideos correlacionaron principalmente con la cobertura del alga, mientras que la abundancia de gasterópodos estuvo condicionada por la turbidez y la de los grupos restantes por la conductividad y temperatura principalmente. El estrecho d

Influenza challenging the diagnosis and management of pulmonary coccidioidomycosis

Funding There was no funding for this manuscript.Peer reviewedPublisher PD

Experimental validation of gallium production and isotope-dependent positron range correction in PET

Abstract Positron range (PR) is one of the important factors that limit the spatial resolution of positron emission tomography (PET) preclinical images. Its blurring effect can be corrected to a large extent if the appropriate method is used during the image reconstruction. Nevertheless, this correction requires an accurate modelling of the PR for the particular radionuclide and materials in the sample under study. In this work we investigate PET imaging with 68Ga and 66Ga radioisotopes, which have a large PR and are being used in many preclinical and clinical PET studies. We produced a 68Ga and 66Ga phantom on a natural zinc target through (p,n) reactions using the 9-MeV proton beam delivered by the 5-MV CMAM tandetron accelerator. The phantom was imaged in an ARGUS small animal PET/CT scanner and reconstructed with a fully 3D iterative algorithm, with and without PR corrections. The reconstructed images at different time frames show significant improvement in spatial resolution when the appropriate PR is applied for each frame, by taking into account the relative amount of each isotope in the sample. With these results we validate our previously proposed PR correction method for isotopes with large PR. Additionally, we explore the feasibility of PET imaging with 68Ga and 66Ga radioisotopes in proton therapy.We acknowledge support from the Spanish MINECO through projects FPA2010-17142, FPA2013-41267-P, CSD-2007-00042 (CPAN), and the RTC-2015-3772-1 grant. We also acknowledge support from Comunidad de Madrid via the TOPUS S2013/MIT-3024 project

Measurement of activity produced by low energy proton beam in metals using off-line PET imaging

Proceeding of: 2011 Nuclear Science Symposium and Medical Imaging Conference, Valencia, España, 23-29 October, 2011In this work, we investigate PET imaging with 68Ga and 66Ga after proton irradiation on a natural zinc foil. The nuclides 68Ga and 66Ga are ideally suited for off line PET monitoring of proton radiotherapy due to their beta decay halflives of 67.71(9) minutes and 9.49(3) hours, respectively, and suitable fl end point energy. The purpose of this work is to explore the feasibility of PET monitoring in hadrontherapy treatments, and to study how the amount of activity and the positron range affect the PET image reconstruction. Profiting from the low energy reaction threshold for production via (p,n) reactions, both 68Ga and 66Ga gallium isotopes have been produced by activation on a natural zinc target by a proton pencil beam. In this way, it is possible to create detailed patterns, such as the Derenzo inspired one employed here. The proton beam was produced by the 5 MV tandetron accelerator at CMAM in Madrid. The energy of this beam (up to 10 MeV) is similar to the residual energy of the protons used for therapy at the distal edge of their path. The activated target was imaged in an ARGUS small animal PETtCT scanner and reconstructed with a fully 3D iterative algorithm, with and without positron range corrections.This work was supported in part by Comunidad de Madrid (ARTEMIS S2009/DPI 1802), Spanish Ministry of Science and Innovation (grants FPA2010 17142 and ENTEPRASE, PSE 300000 2009 5), by European Regional Funds, by CDTI under the CENIT Programme (AMIT Project), UCM (grupos UCM, 910059) and by CPAN, CSPD 2007 [email protected]

Reappraisal of the outcome of healthcare-associated and community-acquired bacteramia: a prospective cohort study

Background: Healthcare-associated (HCA) bloodstream infections (BSI) have been associated with worse outcomes, in terms of higher frequencies of antibiotic-resistant microorganisms and inappropriate therapy than strict community-acquired (CA) BSI. Recent changes in the epidemiology of community (CO)-BSI and treatment protocols may have modified this association. The objective of this study was to analyse the etiology, therapy and outcomes for CA and HCA BSI in our area. Methods: A prospective multicentre cohort including all CO-BSI episodes in adult patients was performed over a 3-month period in 2006–2007. Outcome variables were mortality and inappropriate empirical therapy. Adjusted analyses were performed by logistic regression. Results: 341 episodes of CO-BSI were included in the study. Acquisition was HCA in 56% (192 episodes) of them. Inappropriate empirical therapy was administered in 16.7% (57 episodes). All-cause mortality was 16.4% (56 patients) at day 14 and 20% (71 patients) at day 30. After controlling for age, Charlson index, source, etiology, presentation with severe sepsis or shock and inappropriate empirical treatment, acquisition type was not associated with an increase in 14-day or 30-day mortality. Only an stratified analysis of 14th-day mortality for Gram negatives BSI showed a statically significant difference (7% in CA vs 17% in HCA, p = 0,05). Factors independently related to inadequate empirical treatment in the community were: catheter source, cancer, and previous antimicrobial use; no association with HCA acquisition was found. Conclusion: HCA acquisition in our cohort was not a predictor for either inappropriate empirical treatment or increased mortality. These results might reflect recent changes in therapeutic protocols and epidemiological changes in community pathogens. Further studies should focus on recognising CA BSI due to resistant organisms facilitating an early and adequate treatment in patients with CA resistant BSI

Surveillance of Candida spp Bloodstream Infections: Epidemiological Trends and Risk Factors of Death in Two Mexican Tertiary Care Hospitals

Introduction: Larger populations at risk, broader use of antibiotics and longer hospital stays have impacted on the incidence of Candida sp. bloodstream infections (CBSI).Objective: To determine clinical and epidemiologic characteristics of patients with CBSI in two tertiary care reference medical institutions in Mexico City.Design: Prospective and observational laboratory-based surveillance study conducted from 07/2008 to 06/2010.Methods: All patients with CBSI were included. Identification and antifungal susceptibility were performed using CLSI M27-A3 standard procedures. Frequencies, Mann-Whitney U test or T test were used as needed. Risk factors were determined with multivariable analysis and binary logistic regression analysis.Results: CBSI represented 3.8% of nosocomial bloodstream infections. Cumulative incidence was 2.8 per 1000 discharges (incidence rate: 0.38 per 1000 patient-days). C. albicans was the predominant species (46%), followed by C. tropicalis (26%). C. glabrata was isolated from patients with diabetes (50%), and elderly patients. Sixty-four patients (86%) received antifungals. Amphotericin-B deoxycholate (AmBD) was the most commonly used agent (66%). Overall mortality rate reached 46%, and risk factors for death were APACHE II score >= 16 (OR = 6.94, CI95% = 2.34-20.58, p<0.0001), and liver disease (OR = 186.11, CI95% = 7.61-4550.20, p = 0.001). Full susceptibility to fluconazole, AmBD and echinocandins among C. albicans, C. tropicalis, and C. parapsilosis was observed.Conclusions: the cumulative incidence rate in these centers was higher than other reports from tertiary care hospitals from Latin America. Knowledge of local epidemiologic patterns permits the design of more specific strategies for prevention and preemptive therapy of CBSI.Pfizer Inc.Salvador Zubiran Natl Inst Med Sci & Nutr, Dept Med, Mexico City, DF, MexicoHosp Escuela Tegucigalpa, Tegucigalpa, HondurasUniversidade Federal de São Paulo, Escola Paulista Med, Div Infect Dis, São Paulo, BrazilNatl Canc Inst, Div Infect Dis, Mexico City, DF, MexicoUniv Nacl Colombia, Dept Internal Med, Bogota, ColombiaUniv Peruana Cayetano Heredia, Dept Med, Lima, PeruHosp Vargas Caracas, Caracas, VenezuelaCtr Med Caracas, Caracas, VenezuelaUniv Fed Rio de Janeiro, Univ Hosp, Rio de Janeiro, BrazilUniv Texas Med Sch Houston, Mem Hermann Texas Med Ctr, Dept Med, Houston, TX USAUniv Fed Parana, Hosp Clin, BR-80060000 Curitiba, Parana, BrazilUniv Chile, Fac Med, Hosp Luis Calvo Mackenna, Dept Pediat, Santiago 7, ChileUniv Desarrollo, Clin Alemana, Dept Med, Santiago, ChileHosp Clin Jose San Martin, Infect Dis Unit, Buenos Aires, DF, ArgentinaPontificia Univ Catolica Ecuador, Fac Med, Hosp Vozandes, Quito, EcuadorUniversidade Federal de São Paulo, Escola Paulista Med, Div Infect Dis, São Paulo, BrazilPfizer Inc.: INF-168Web of Scienc

Quasiexperimental intervention study protocol to optimise the use of new antibiotics in Spain: the NEW_SAFE project

[Introduction] Ceftaroline, tedizolid, dalbavancin, ceftazidime-avibactam and ceftolozane-tazobactam are novel antibiotics used to treat infections caused by multidrug-resistant pathogens (MDR). Their use should be supervised and monitored as part of an antimicrobial stewardship programme (ASP). Appropriate use of the new antibiotics will be improved by including consensual indications for their use in local antibiotic guidelines, together with educational interventions providing advice to prescribers to ensure that the recommendations are clearly understood.[Methods and analysis] This study will be implemented in two phases. First, a preliminary historical cohort (2017–2019) of patients from 13 Andalusian hospitals treated with novel antibiotics will be analysed. Second, a quasiexperimental intervention study will be developed with an interrupted time-series analysis (2020–2021). The intervention will consist of an educational interview between prescribers and ASP leaders at each hospital to reinforce the proper use of novel antibiotics. The educational intervention will be based on a consensus guideline designed and disseminated by leaders after the retrospective cohort data have been analysed. The outcomes will be acceptance of the intervention and appropriateness of prescription. Incidence of infection and colonisation with MDR organisms as well as incidence of Clostridioides difficile infection will also be analysed. Changes in prescription quality between periods and the safety profile of the antibiotics in terms of mortality rate and readmissions will also be measured.[Ethics and dissemination] Ethical approval will be obtained from the Andalusian Coordinating Institutional Review Board. The study is being conducted in compliance with the protocol and regulatory requirements consistent with International Council of Harmonisation E6 Good Clinical Practice and the ethical principles of the latest version of the Declaration of Helsinki. The results will be published in peer-reviewed journals and disseminated at national and international conferences.[Trial registration number] NCT03941951; Pre-results.The study is funded by the Consejería de Salud, Junta de Andalucía, grant PI-0077-2018. The investigators also receive funds for research from the Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001) through the Plan Nacional de I+D+ i 2013‐2016, cofinanced by European Development Regional Fund “A way to achieve Europe”, Operative program Intelligent Growth 2014‐2020

Quasiexperimental intervention study protocol to optimise the use of new antibiotics in Spain: the NEW_SAFE project

Introduction Ceftaroline, tedizolid, dalbavancin, ceftazidime-avibactam and ceftolozane-tazobactam are novel antibiotics used to treat infections caused by multidrug-resistant pathogens (MDR). Their use should be supervised and monitored as part of an antimicrobial stewardship programme (ASP). Appropriate use of the new antibiotics will be improved by including consensual indications for their use in local antibiotic guidelines, together with educational interventions providing advice to prescribers to ensure that the recommendations are clearly understood. Methods and analysis This study will be implemented in two phases. First, a preliminary historical cohort (2017-2019) of patients from 13 Andalusian hospitals treated with novel antibiotics will be analysed. Second, a quasiexperimental intervention study will be developed with an interrupted time-series analysis (2020-2021). The intervention will consist of an educational interview between prescribers and ASP leaders at each hospital to reinforce the proper use of novel antibiotics. The educational intervention will be based on a consensus guideline designed and disseminated by leaders after the retrospective cohort data have been analysed. The outcomes will be acceptance of the intervention and appropriateness of prescription. Incidence of infection and colonisation with MDR organisms as well as incidence ofClostridioides difficileinfection will also be analysed. Changes in prescription quality between periods and the safety profile of the antibiotics in terms of mortality rate and readmissions will also be measured. Ethics and dissemination Ethical approval will be obtained from the Andalusian Coordinating Institutional Review Board. The study is being conducted in compliance with the protocol and regulatory requirements consistent with International Council of Harmonisation E6 Good Clinical Practice and the ethical principles of the latest version of the Declaration of Helsinki. The results will be published in peer-reviewed journals and disseminated at national and international conferences

[Personalidades varias] [Material gráfico]: [(VII)]

Contiene fotografías pertenecientes al archivo fotográfico del diario "Región", publicadas entre 1971 y 1983Algunas fotos no indican autoría; el resto firmadas por Estudios Fotográficos Álvarez (Oviedo), Foto Sanso, Infomación Gráfica Sierra (Oviedo), Cachero (Oviedo), Foto Segura (Oviedo), Foto Gudín (Luarca), Astra (Oviedo), Foto E. Gar (Oviedo), Foto Juan, Estudio Fotográfico Hnos. Esteban, Foto Paco (Mieres), Cifra Gráfica, Foto Alonso (Mieres